Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Didier Trono, Henning Paul-Julius Stahlberg, Priscilla Turelli, Florence Pojer, Charlène Mireille Raymonde Raclot, Kelvin Ka Ching Lau, Myriam Isabelle Lamrayah, Jérémy Campos, Vanessa Genet
2023
Article

Résumé

Due to the rapid evolution of SARS-CoV-2 to variants with reduced sensitivity to vaccine-induced humoral immunity and the near complete loss of protective efficacy of licensed therapeutic monoclonal antibodies, we isolated a potent, broad-spectrum neutralizing antibody that could potentially provide prophylactic protection to immunocompromised patient populations.

Source officielle

https://infoscience.epfl.ch/record/306177?ln=fr

À propos de ce résultat

Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Peptide-based virucidal drugs

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

Poloxamers Have Vaccine-Adjuvant Properties by Increasing Dissemination of Particulate Antigen at Distant Lymph Nodes

Peptide-based virucidal drugs

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

Poloxamers Have Vaccine-Adjuvant Properties by Increasing Dissemination of Particulate Antigen at Distant Lymph Nodes